Regeneron Pharmaceuticals, Inc.

Memorial Sloan Kettering Cancer Center

Eureka Therapeutics, Inc.

Regeneran Pharmaceuticals, Inc.

Other

Juno Therapeutics Gmbh

Eric L Smith

Samuel H Davis

Nicholas J Papadopoulos

Cheng Liu

Renier J Brentjens

Joel H Martin

Jessica Kirshner

Gavin Thurston

Ashique Rafique

Chia-Yang Lin

Lauric Haber

Tong Zhang

Kara Olson

Andrew J Murphy

Margaret Karow

Supriya Patel

Sean Stevens

Gang Chen

James P Fandl

Tammy T Huang

Jeanette L Fairhurst

Kevin J Pobursky

Alison Crawford

Erica Pyles

Thomas Nittoli

Douglas MacDonald

Frank Delfino

Allen Radin

George D Yancopoulos

Marcus Kelly

Dimitris Skokos

Bindu Varghese

Ka-Man Venus Lai

Yan Chen

Steven M Shamah

Csaba Pazmany

Semih Ullah Tareen

Israel Lowy

Kurt R Zimmerman

Hong Liu

Nina Liu

Michael Rosconi

Irene Noguera-Troise

Aynur Hermann

Erica Ullman

Thomas Craig Meagher

Jiaxi Wu

Maria Del Pilar Molina-Portela

Olga Sineshchekova

Yashu Liu

David DiLillo

Drew Dudgeon

Janelle Waite

Jennifer A Finney

Ryan McKay

Sandra Coetzee

Jui Dutta-Simmons

Rupesh Amin

Blythe D Sather

Qian Zhang

Collin Hauskins

John Rudge

Aye Chen

Melissa Works

Dayong Guo

Kimberly Harrington

Ruth Salmon

Rebecca Wu

Erik Hess

Cyr De Imus

Jon Jones

Audrey Olshefsky

Stefan Ponko

Mariana Cota Stirner

Nicholas W Gale

Carrie Brownstein

Chiayang Lin

Joyce Wei

Renier J Brent Jens

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Antigen binding molecule formats

The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

The present disclosure relates to IL2 agonists with improved therapeutic profiles.

IL2 agonists and methods of use thereof

The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.

Compositions and methods for treating cytokine release syndrome

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Readily isolated bispecific antibodies with native immunoglobulin format

The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof

IL2 and peptide-MHC complex fusion proteins and methods of use thereof

The present invention provides multispecific antigen-binding molecules that bind both a T-cell antigen (e.g., CD3) and a target antigen (e.g., a tumor associated antigen, a viral or bacterial antigen), and which include a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T-cell antigen binding, and uses thereof.

Multispecific antigen-binding molecules for cell targeting and uses thereof

Growing community of inventors

New York, NY, United States of America

Eric L Smith